دورية أكاديمية
Nanosystems for gene therapy targeting brain damage caused by viral infections.
| العنوان: | Nanosystems for gene therapy targeting brain damage caused by viral infections. |
|---|---|
| المؤلفون: | da Silva TN; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil., de Lima EV; Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil., Barradas TN; Departamento de Ciências Farmacêuticas, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, 36036-900, Brazil., Testa CG; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil., Picciani PHS; Instituto de Macromoléculas Professora Eloisa Mano, Universidade Federal do Rio de Janeiro (IMA/UFRJ), Rio de Janeiro, RJ, 21941-598, Brazil., Figueiredo CP; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil., do Carmo FA; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil., Clarke JR; Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil.; Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, 21941-902, Brazil. |
| المصدر: | Materials today. Bio [Mater Today Bio] 2022 Dec 17; Vol. 18, pp. 100525. Date of Electronic Publication: 2022 Dec 17 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101757228 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-0064 (Electronic) Linking ISSN: 25900064 NLM ISO Abbreviation: Mater Today Bio Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: [London] : Elsevier Ltd., [2019]- |
| مستخلص: | Several human pathogens can cause long-lasting neurological damage. Despite the increasing clinical knowledge about these conditions, most still lack efficient therapeutic interventions. Gene therapy (GT) approaches comprise strategies to modify or adjust the expression or function of a gene, thus providing therapy for human diseases. Since recombinant nucleic acids used in GT have physicochemical limitations and can fail to reach the desired tissue, viral and non-viral vectors are applied to mediate gene delivery. Although viral vectors are associated to high levels of transfection, non-viral vectors are safer and have been further explored. Different types of nanosystems consisting of lipids, polymeric and inorganic materials are applied as non-viral vectors. In this review, we discuss potential targets for GT intervention in order to prevent neurological damage associated to infectious diseases as well as the role of nanosized non-viral vectors as agents to help the selective delivery of these gene-modifying molecules. Application of non-viral vectors for delivery of GT effectors comprise a promising alternative to treat brain inflammation induced by viral infections. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2022 Published by Elsevier Ltd.) |
| References: | Acta Neuropathol. 2016 Feb;131(2):159-184. (PMID: 26659576) Mol Neurobiol. 2019 Mar;56(3):1897-1907. (PMID: 29978423) Acta Biomater. 2022 Jan 15;138:478-490. (PMID: 34757231) J Control Release. 2021 Oct 10;338:80-104. (PMID: 34375690) Nat Commun. 2019 Jul 24;10(1):3307. (PMID: 31341171) Drug Discov Today. 2022 May;27(5):1431-1440. (PMID: 35017085) Int J Mol Sci. 2020 May 25;21(10):. (PMID: 32466154) Adv Drug Deliv Rev. 2014 Feb;66:110-6. (PMID: 24384374) J Control Release. 2006 Nov 28;116(2):255-64. (PMID: 16914222) Eur J Pharm Sci. 2015 Oct 12;78:19-30. (PMID: 26118442) Nat Rev Drug Discov. 2021 Feb;20(2):101-124. (PMID: 33277608) Adv Healthc Mater. 2021 May;10(9):e2002200. (PMID: 33644993) Anim Reprod Sci. 2009 Oct;115(1-4):158-68. (PMID: 19131190) Int J Pharm. 2020 Jan 5;573:118814. (PMID: 31759101) Biomed Res Int. 2021 Feb 15;2021:8844030. (PMID: 33644232) Adv Colloid Interface Sci. 2016 Jul;233:161-175. (PMID: 26265376) Bioeng Transl Med. 2021 Oct 20;7(1):e10258. (PMID: 35079633) Biomed Mater. 2022 Feb 07;17(2):. (PMID: 35073527) Virol Sin. 2013 Dec;28(6):345-51. (PMID: 24213989) Adv Funct Mater. 2011 Feb 8;21(3):434-440. (PMID: 23393493) Expert Opin Drug Discov. 2022 Jan;17(1):19-25. (PMID: 34461793) J Control Release. 2021 Oct 10;338:680-693. (PMID: 34517042) Curr Top Med Chem. 2015;15(13):1179-95. (PMID: 25858132) Pharmaceutics. 2020 Dec 15;12(12):. (PMID: 33334049) Drug Deliv Transl Res. 2021 Jun;11(3):748-787. (PMID: 32748035) Chem Phys Lipids. 2012 May;165(4):414-23. (PMID: 22715503) J Nanobiotechnology. 2018 Sep 19;16(1):71. (PMID: 30231877) Nanomedicine. 2017 Nov;13(8):2533-2544. (PMID: 28736294) Pathogens. 2022 Jan 02;11(1):. (PMID: 35056000) Front Cell Neurosci. 2021 Apr 09;15:662578. (PMID: 33897376) Front Oncol. 2019 Apr 24;9:297. (PMID: 31069169) Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221080974. (PMID: 35253549) Biomaterials. 2015 Aug;60:151-60. (PMID: 26000961) ACS Nano. 2015 Jun 23;9(6):6511-21. (PMID: 26057729) Adv Drug Deliv Rev. 2014 May;71:2-14. (PMID: 23981489) Neurology. 2007 Oct 30;69(18):1789-99. (PMID: 17914061) Infect Dis Clin North Am. 2019 Dec;33(4):xiii-xix. (PMID: 31668202) Antivir Ther. 2016;21(3):225-35. (PMID: 26669609) Molecules. 2019 Oct 17;24(20):. (PMID: 31627389) PLoS One. 2019 Jul 22;14(7):e0219995. (PMID: 31329627) Signal Transduct Target Ther. 2021 Feb 8;6(1):53. (PMID: 33558455) J Neuroimmune Pharmacol. 2019 Jun;14(2):157-172. (PMID: 30456443) Nanomedicine. 2017 Jan;13(1):209-218. (PMID: 27553077) Viruses. 2021 Feb 22;13(2):. (PMID: 33671821) J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):509-516. (PMID: 28520614) Mol Pharm. 2012 May 7;9(5):1280-90. (PMID: 22420286) Int J Pharm. 2019 Mar 10;558:250-260. (PMID: 30641179) Brain Behav Immun Health. 2020 Jul 18;7:100105. (PMID: 34589866) Nanomedicine. 2018 Oct;14(7):2095-2102. (PMID: 29969727) Ann Clin Transl Neurol. 2018 May 16;5(6):752-762. (PMID: 29928658) J Colloid Interface Sci. 2015 Jun 1;447:8-15. (PMID: 25689522) Chem Rev. 2016 Feb 24;116(4):2602-63. (PMID: 26854975) Mol Pharm. 2016 Jun 6;13(6):1791-9. (PMID: 27177352) J Drug Target. 2019 Aug;27(7):742-761. (PMID: 30239255) Int J Nanomedicine. 2018 Jun 26;13:3679-3687. (PMID: 29983562) Nat Rev Genet. 2020 Apr;21(4):255-272. (PMID: 32042148) Front Microbiol. 2021 Nov 15;12:767104. (PMID: 34867899) J Control Release. 2018 Aug 10;283:175-189. (PMID: 29883694) Sci Adv. 2020 Jan 10;6(2):eaaw6284. (PMID: 31950075) Materials (Basel). 2018 Feb 09;11(2):. (PMID: 29425146) Polymers (Basel). 2019 Apr 25;11(4):. (PMID: 31027272) Nanomaterials (Basel). 2021 Oct 23;11(11):. (PMID: 34835580) AAPS J. 2015 Sep;17(5):1041-54. (PMID: 25956384) J Neurovirol. 2018 Apr;24(2):141-145. (PMID: 28752495) Mater Sci Eng C Mater Biol Appl. 2021 Jan;120:111756. (PMID: 33545897) ACS Appl Mater Interfaces. 2015 Jul 22;7(28):15240-55. (PMID: 26120905) Adv Healthc Mater. 2021 Jan;10(1):e2001238. (PMID: 33191667) Mol Pharm. 2020 Jun 1;17(6):1996-2005. (PMID: 32365295) Theranostics. 2018 Feb 5;8(6):1481-1493. (PMID: 29556336) Biomater Res. 2019 Mar 12;23:8. (PMID: 30915230) Sci Rep. 2017 May 12;7(1):1862. (PMID: 28500326) Brain Res. 2009 Jul 28;1282:142-55. (PMID: 19477169) Expert Opin Drug Deliv. 2016 Oct;13(10):1433-45. (PMID: 27249310) Adv Healthc Mater. 2019 Jan;8(2):e1801359. (PMID: 30549448) J Mater Chem B. 2015 Oct 14;3(38):7477-7493. (PMID: 32262631) Lancet HIV. 2020 Jul;7(7):e504-e513. (PMID: 32621876) Adv Drug Deliv Rev. 2021 Sep;176:113851. (PMID: 34224787) J Pharmacol Exp Ther. 2020 Sep;374(3):354-365. (PMID: 32561686) Front Pharmacol. 2019 Jul 01;10:724. (PMID: 31312139) Adv Sci (Weinh). 2022 Sep;9(26):e2201740. (PMID: 35851766) Neurol Res. 2010 Oct;32(8):801-9. (PMID: 20483026) Environ Chem Lett. 2020;18(3):703-727. (PMID: 32206050) Molecules. 2020 Sep 01;25(17):. (PMID: 32882920) J Control Release. 2015 Feb 28;200:60-70. (PMID: 25559178) Drug Deliv Transl Res. 2017 Aug;7(4):497-506. (PMID: 28315051) ACS Omega. 2018 Jan 31;3(1):208-217. (PMID: 30023772) Nanomedicine (Lond). 2015 Jul;10(12):1923-40. (PMID: 26139126) Nat Rev Drug Discov. 2013 Nov;12(11):847-65. (PMID: 24172333) Nat Rev Genet. 2014 Aug;15(8):541-55. (PMID: 25022906) Nanomedicine (Lond). 2018 Jan;13(1):89-103. (PMID: 29199893) Polymers (Basel). 2020 Nov 06;12(11):. (PMID: 33171983) Biosens Bioelectron. 2019 Sep 15;141:111158. (PMID: 31323605) Biomaterials. 2017 Mar;121:155-166. (PMID: 28088077) J Interferon Cytokine Res. 2020 Jan;40(1):1-18. (PMID: 31436502) J Drug Deliv. 2013;2013:340315. (PMID: 23936656) Mol Ther. 2017 Jul 5;25(7):1467-1475. (PMID: 28412170) J Drug Target. 2020 Feb;28(2):111-128. (PMID: 31195838) Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):129-137. (PMID: 26900977) Metab Brain Dis. 2022 Aug 4;:. (PMID: 35922735) 3 Biotech. 2020 Apr;10(4):147. (PMID: 32181109) Chem Biol Interact. 2022 Jul 1;361:109960. (PMID: 35533733) Adv Drug Deliv Rev. 2020;156:80-118. (PMID: 32980449) Polymers (Basel). 2017 May 01;9(5):. (PMID: 30970840) Nanomaterials (Basel). 2022 Jun 22;12(13):. (PMID: 35807977) Neurol Res Pract. 2019 Jun 11;1:20. (PMID: 33324886) RSC Adv. 2019 Feb 25;9(12):6460-6481. (PMID: 35518468) Gene. 2016 Dec 15;594(2):183-189. (PMID: 27593564) Mater Sci Eng C Mater Biol Appl. 2017 Nov 1;80:771-784. (PMID: 28866227) Life Sci. 2022 Apr 1;294:120375. (PMID: 35123997) Curr Treat Options Infect Dis. 2020 Sep;12(3):227-242. (PMID: 33551684) Zh Vopr Neirokhir Im N N Burdenko. 2015;79(2):21-32. (PMID: 26146041) Nanomaterials (Basel). 2020 Jul 19;10(7):. (PMID: 32707641) Mol Ther Nucleic Acids. 2018 Sep 7;12:645-657. (PMID: 30081235) J Control Release. 2019 Nov 10;313:80-95. (PMID: 31622695) Biotechnol Adv. 2020 May - Jun;40:107502. (PMID: 31887345) Pharmaceuticals (Basel). 2019 Apr 17;12(2):. (PMID: 30999590) Mol Ther. 2012 Jul;20(7):1298-304. (PMID: 22525514) J Control Release. 2021 Apr 10;332:312-336. (PMID: 33652113) Mol Ther Oncolytics. 2021 Oct 30;23:432-446. (PMID: 34853814) Int J Nanomedicine. 2020 Mar 30;15:2131-2150. (PMID: 32280211) Molecules. 2018 Apr 18;23(4):. (PMID: 29670005) Nanomedicine (Lond). 2016 Apr;11(7):833-49. (PMID: 26980585) Front Bioeng Biotechnol. 2021 Jul 20;9:701031. (PMID: 34354988) J Med Chem. 2021 Jul 22;64(14):9592-9638. (PMID: 34251209) Int J Pharm. 2017 Aug 7;528(1-2):675-691. (PMID: 28629982) Biomaterials. 2016 Jan;75:193-202. (PMID: 26513413) Int J Pharm. 2021 Oct 25;608:121095. (PMID: 34543617) Int J Mol Sci. 2017 Aug 05;18(8):. (PMID: 28783051) Int J Pharm. 2014 Jan 1;459(1-2):70-83. (PMID: 24286924) AAPS J. 2021 Jun 2;23(4):78. (PMID: 34076797) Adv Funct Mater. 2017 Dec 8;27(46):. (PMID: 29755309) Int J Nanomedicine. 2019 Jul 30;14:5895-5909. (PMID: 31440051) Front Aging Neurosci. 2016 Apr 05;8:68. (PMID: 27092073) J Neurol Neurosurg Psychiatry. 1997 Sep;63(3):321-6. (PMID: 9328248) Innate Immun. 2021 Feb;27(2):109-117. (PMID: 32903111) Acta Biomater. 2019 Aug;94:44-63. (PMID: 31082570) Mol Ther. 2022 May 4;30(5):2078-2091. (PMID: 34762817) Int J Mol Sci. 2020 Feb 17;21(4):. (PMID: 32079277) Nanomedicine (Lond). 2021 Jun;16(13):1081-1095. (PMID: 33960213) Gene Ther. 2017 Aug;24(8):441-452. (PMID: 28504657) Chem Soc Rev. 2012 Nov 7;41(21):7147-94. (PMID: 22885409) J Neurol. 2012 Oct;259(10):2019-30. (PMID: 22527234) Pharm Res. 2021 Mar;38(3):473-478. (PMID: 33660201) Nanomaterials (Basel). 2018 Apr 24;8(5):. (PMID: 29695068) Int J Mol Sci. 2021 Jul 14;22(14):. (PMID: 34299164) Avicenna J Med Biotechnol. 2013 Apr;5(2):68-77. (PMID: 23799175) ACS Nano. 2013 Jan 22;7(1):347-64. (PMID: 23234474) Neurobiol Dis. 2006 Sep;23(3):612-20. (PMID: 16843674) Acta Biomater. 2016 Apr 15;35:98-108. (PMID: 26873365) Pharmaceutics. 2021 May 15;13(5):. (PMID: 34063469) Drug Deliv. 2018 Nov;25(1):1516-1525. (PMID: 29968512) Drug Discov Today. 2021 Jul;26(7):1602-1619. (PMID: 33781953) Brain Behav Immun. 2019 Aug;80:227-237. (PMID: 30872089) Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Mar-Apr;8(2):271-99. (PMID: 26314803) Biomed Pharmacother. 2019 Mar;111:666-675. (PMID: 30611991) Pharmaceutics. 2021 Feb 06;13(2):. (PMID: 33561939) J Control Release. 2016 Aug 10;235:34-47. (PMID: 27208862) Lancet Neurol. 2020 Oct;19(10):799-801. (PMID: 32949531) Int J Pharm. 2020 Sep 25;587:119701. (PMID: 32736018) J Pharm Sci. 2021 Jul;110(7):2609-2624. (PMID: 33812887) Artif Cells Nanomed Biotechnol. 2016;44(1):381-91. (PMID: 25222036) J Neuroimmune Pharmacol. 2017 Mar;12(1):133-151. (PMID: 28028734) Polymers (Basel). 2022 Feb 05;14(3):. (PMID: 35160606) Chem Rev. 2015 Mar 11;115(5):2109-35. (PMID: 25757742) Nano Converg. 2018 Nov 30;5(1):35. (PMID: 30499047) Brain Res Bull. 2019 Aug;150:216-230. (PMID: 31173859) Int J Nanomedicine. 2015 Feb 02;10:975-99. (PMID: 25678787) J Control Release. 2006 Aug 10;114(1):100-9. (PMID: 16831482) Expert Opin Drug Deliv. 2017 Mar;14(3):353-371. (PMID: 27434618) Molecules. 2019 Dec 27;25(1):. (PMID: 31892180) |
| فهرسة مساهمة: | Keywords: Brain inflammation; Dendrimers; Gene therapy; Inorganic nanoparticles; Lipid nanosystems; Polymeric nanoparticles; Viral infection; iRNA |
| تواريخ الأحداث: | Date Created: 20230109 Latest Revision: 20230111 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9816812 |
| DOI: | 10.1016/j.mtbio.2022.100525 |
| PMID: | 36619201 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!